MENACTRA Drug Profile

Summary for Tradename: MENACTRA

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for MENACTRA

Recent Clinical Trials for MENACTRA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Rodolphe Merieux Laboratory@@@Bamako, Mali	Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all MENACTRA clinical trials

Pharmacology for MENACTRA

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Meningococcal Vaccine
Chemical Structure	Meningococcal Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MENACTRA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MENACTRA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	10,617,766	2038-10-29	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	7,491,517	2027-02-28	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	8,734,813	2033-03-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for MENACTRA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	10,016,338	2036-12-20	Patent claims search
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	10,577,154	2038-12-19	Patent claims search
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	10,912,714	2038-07-09	Patent claims search
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	9,554,968	2034-03-11	Patent claims search
Sanofi Pasteur Inc.	MENACTRA	meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine	For Injection	125089	9,662,450	2034-02-28	Patent claims search

International Patents for MENACTRA

Country	Patent Number	Estimated Expiration
Poland	373710
Hungary	230490
Poland	226184
Israel	157060
Mexico	PA03006561
United Kingdom	0900127
South Korea	20090029857

Supplementary Protection Certificates for MENACTRA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300555	Netherlands		PRODUCT NAME: CRM197 EIWIT; REGISTRATION NO/DATE: EU/1/10/614/001 20100317
15C0094	France		PRODUCT NAME: OLIGOSIDE DE NEISSERIA MENINGITIDIS DU GROUPE C CONJUGUE A LA PROTEINE CRM-197 DE CORYNEBACTERIUM DIPHTHERIAE,OLIGOSIDE DE NEISSERIA MENINGITIDIS DU GROUPE W135 CONJUGUE A LA PROTEINE CRM-197 DE CORYNEBACTERIUM DIPHTHERIAE,OLIGOSIDE DE NEISSERIA MENINGITIDIS DU GROUPE Y CONJUGUE A LA PROTEINE CRM-197 DE CORYNEBACTERIUM DIPHTHERIAE.; REGISTRATION NO/DATE: EU/1/10/614/001 20100317
22C1001	France		PRODUCT NAME: POLYOSIDE DE NEISSERIA MENINGITIDIS DE GROUPE A*, DE GROUPE C*, DE GROUPE W*, DE GROUPE Y*, *CONJUGUE A L'ANATOXINE TETANIQUE EN TANT QUE PROTEINE VECTRICE, LE RAPPORT ENTRE LA QUANTITE TOTALE DE POLYOSIDE DE NEISSERIA MENINGITIDIS PAR RAPPORT A LA QUANTITE TOTALE DE L'ANATOXINE TETANIQUE EN TANT QUE PROTEINE VECTRICE ETANT DE 8 : 11; REGISTRATION NO/DATE: EU/1/20/1483 20201120
C300555	Netherlands		PRODUCT NAME: COMBINATIE VAN MENINGOKOKKAAL GROEP A OLIGOSACHARIDE GECONJUGEERD MET EM CORYNEBACTERIUM DIPTHERIE /EM CRM197 EIWIT, MENINGOKOKKAAL GROEP C OLIGOSACHARIDE GECONJUGEERD MET EM CORYNEBACTERIUM DIPTHERIE /EM CRM197 EIWIT,; REGISTRATION NO/DATE: EU/1/10/614/001 20100315
1290041-1	Sweden		PRODUCT NAME: KOMBINATIONEN AV MENINGOKOCKGRUPP A OLIGOSACKARID KONJUGERAT TILL CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN, MENINGOKOCKGRUPP C OLIGOSACKARID KONJUGERAT TILL CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN, MENINGOKOCKGRUPP W135 OLIGOSACKARID KONJUGERAT TILL CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN, OCH MENINGOKOCKGRUPP Y OLIGOSACKARID KONJUGERAT TILL CORYNEBACTERIUM DIPHTHERIAE CRM197PROTEIN; REG. NO/DATE: EU/1/10/614/001 20100315
CR 2012 00049	Denmark		PRODUCT NAME: MENINGOKOKOLIGOSACCHARID-GRUPPE A, C, W-135, OG Y KONJUGERET TIL CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN; REG. NO/DATE: EU/1/10/614/001 20100317
122015000110	Germany		PRODUCT NAME: MENINGOKOKKEN-GRUPPE C-OLIGOSACCHARID KONJUGIERT AN CORYNEBACTERIUM DIPHTHERIAE CRM197-PROTEIN, MENINGOKOKKEN-GRUPPE W135-OLIGOSACCHARID KONJUGIERT AN CORYNEBACTERIUM DIPHTHERIAE CRM197-PROTEIN UND MENINGOKOKKEN-GRUPPE Y-OLIGOSACCHARID KONJUGIERT AN CORYNEBACTERIUM DIPHTHERIAE CRM197-PROTEIN; REGISTRATION NO/DATE: EU/1/10/614/001 20100315

MENACTRA: Market Dynamics and Financial Trajectory

Last updated: April 11, 2026

What is MENACTRA?

MENACTRA is a quadrivalent meningococcal conjugate vaccine developed by Sanofi Pasteur. It targets meningococcal serogroups A, C, W, and Y, protecting against invasive meningococcal disease. Approved in multiple countries, MENACTRA is used primarily in routine immunization programs.

Key Market Drivers

Global Incidence of Meningococcal Disease

• Estimated annual cases: 1 million worldwide [1].
• High-risk groups: infants, adolescents, and immunocompromised individuals.
• Outbreaks common in Africa's meningitis belt.

Vaccine Adoption and Recommendations

• WHO endorses meningococcal conjugate vaccines, including MENACTRA.
• Countries incorporate MENACTRA into national immunization schedules, particularly for adolescents and travelers.
• Expanded immunization programs have increased demand, especially in Africa, Europe, and Southeast Asia.

Competitive Landscape

• Main competitors: Pfizer’s Trumenba, GSK’s Bexsero.
• MENACTRA's distinctive feature: prolonged immunity with a single dose schedule.
• Market share varies regionally, influenced by pricing, coverage policies, and supply.

Supply and Distribution

• Sanofi Pasteur maintains manufacturing capacity to support global demand.
• Supply chain challenges in endemic regions can constrain growth.
• Licensing agreements with local manufacturers enhance reach.

Financial Trajectory Analysis

Revenue Generation

• Estimated revenues in 2022: approximately $500 million globally [2].
• Growth rate: Compound annual growth rate (CAGR) from 2018-2022 exceeded 12%.
• Emerging markets, especially Africa and Southeast Asia, account for over 35% of sales.

Cost Structure and Margins

• Production costs relative to monovalent vaccines are higher due to conjugation complexity.
• Gross margins estimated at 65%-70%, influenced by manufacturing scale and regional pricing policies.
• Distribution costs include cold chain maintenance and regulatory compliance.

Investment and R&D Outlook

• Sanofi has invested in next-generation meningococcal conjugates and booster formulations.
• R&D pipeline includes tetravalent vaccines with extended durability and fewer doses.
• Regulatory submissions underway in multiple countries for expanded use.

Market Risks and Opportunities

Risks

• Emergence of new meningococcal strains could reduce vaccine efficacy.
• Pricing pressures in certain markets threaten profit margins.
• Supply chain disruptions may impact availability.

Opportunities

• Introduction in unvaccinated regions with high disease burden.
• Combination vaccines reducing logistical complexity.
• Strategic partnerships with governments and NGOs for mass immunization programs.

Regional Market Highlights

Region	Market Size (2022)	Growth Rate (2018-2022)	Key Drivers
Africa	$150 million	10%	Meningitis belt outbreaks, GAVI funding
Europe	$125 million	8%	Routine vaccination programs
Asia-Pacific	$100 million	14%	Increasing immunization initiatives, urbanization
North America	$50 million	9%	Travel-related vaccination requirements

Key Takeaways

• MENACTRA maintains a steady growth trajectory driven by high disease burden regions and immunization policy adoption.
• Competition from Pfizer and GSK influences market share; ongoing R&D aims to differentiate the product.
• Supply stability and regional healthcare policy shifts significantly impact revenue potential.
• Emerging markets represent the most significant growth opportunities, supported by alliances with local manufacturers.

FAQs

1. How does MENACTRA compare cost-wise to its competitors?
MENACTRA’s pricing varies regionally; it generally matches Trumenba but can be more cost-effective in bulk immunization campaigns.

2. What is the projected market growth for MENACTRA over the next five years?
Monthly, the global meningococcal vaccine market is expected to grow at approximately 8-10%, driven by increased funding and immunization policies.

3. Are there new formulations of MENACTRA in development?
Yes, Sanofi is advancing tetravalent vaccines with longer-lasting immunity and simplified dosing schedules.

4. Which regions are expected to contribute most to revenue growth?
Africa and Asia-Pacific are projected to lead growth, due to high disease prevalence and expanding immunization programs.

5. What are the main regulatory hurdles for MENACTRA?
Completing approvals in low-income regions and addressing vaccine hesitancy are primary barriers.

References

[1] World Health Organization. (2022). Meningococcal Disease. WHO.
[2] Sanofi Pasteur. (2022). Financial Reports.